Mirvetuximab Soravtansine: A New Standard of Care in Ovarian Cancer?
The response rate observed with mirvetuximab soravtansine was nearly triple the benchmark set in prior studies.
The response rate observed with mirvetuximab soravtansine was nearly triple the benchmark set in prior studies.
The median overall survival was 147.8 months for patients with MAPK-mutated tumors and 89.5 months for patients without MAPK mutations.
In a study of more than 5000 patients with advanced ovarian cancer, 56% received first-line maintenance therapy.
Intraperitoneal carboplatin can prolong progression-free survival, but not overall survival, in patients with ovarian cancer.
Olaparib did improve the time to subsequent treatment and time to discontinuation or death.
The tool, called the “BLOODS score,” was developed to help identify patients who may benefit from preoperative planning and blood-saving techniques.
The 4-year overall survival rate was similar with adjuvant chemotherapy and without it.
Lower-extremity lymphedema is tied to lower physical functioning and a need for help with activities of daily living.
Researchers evaluated the association between metformin and survival in women with type 2 diabetes and 3 hormone-related cancers — breast, ovarian, and endometrial cancer.
Patients who used the tool under their own direction or under nurse direction had better symptom control than did patients treated with enhanced usual care.